Abstract:Abstract Background Endoscopic healing (EH) is the major long-term treatment target for inflammatory bowel diseases (IBD) in adults and paediatric patients. However, EH may not represent disease clearance. Hence, risk of relapse remains high and treatment discontinuation after reaching EH often results in disease exacerbation. We aimed to identify persistent cellular, molecular and microbial drivers of IBD under EH and longitudinally collected endoscopic biopsies from paediatric patients for analysis of single T-cell and bulk transcriptomics as well as mucosa-associated microbiota. Methods We followed disease trajectories of paediatric IBD patients treated according to international guidelines and collected mucosal biopsies from the terminal ileum (TI) and sigmoid colon (SC) at baseline (T1) and after approximately 3-12 months (T2) to assess EH. Non-IBD controls showed no macroscopic or histologic signs of inflammation. Host RNA and bacterial DNA were simultaneously extracted from single biopsies for bulk RNA-seq, and 16S rRNA seq. A second biopsy was used for isolation of lamina propria mononuclear cells (LPMCs), followed by CD45+, CD3+ cell sorting and single T-cell analysis (10X Genomics). Data were quality controlled and integrated. Results 217 biopsies (135 simultaneous extraction of host RNA and bacterial DNA; 82 single T-cell analysis) from 32 paediatric IBD patients (mean age 13 ± 3.5 years, 21 Crohn’s disease [CD], 11 ulcerative colitis [UC]; T1 = 32, T2 = 32, T > 2 = 6) and 5 non-IBD controls were analysed. Time between T1 and T2 averages 40 ± 22 weeks. At baseline, 15 patients (14 CD, 1 UC) were newly diagnosed and 31/32 patients had active mucosal inflammation. Twenty-two patients (71%) achieved EH at T2 (SES-CED ≤2 and absence of ulcerations), mostly on anti-TNF therapy. One patient (EH at T1) experienced relapsing disease within 10 weeks after discontinuing medication. In the bulk RNA-seq, we identified 299 differential expressed genes (DEGs; corrected p-value <0.05, FC >2.0), such as DUOX2, SAA2-SAA4, FCGR3B and NOS2, that are associated with active IBD and remained upregulated in EH in contrast to non-IBD controls. In addition single cell analysis revealed an IBD-specific pathogenic Th17 cluster that continued to exist in EH and showed high correlation with top DEGs after data integration. 16S rRNA gene seq highlighted highly individual mucosa-associated bacterial profiles and a reduced α-diversity in active and EH compared to non-IBD controls. Conclusion A persisting IBD signature in EH reflects ongoing cellular, molecular and microbial activity in comparison to non-IBD controls despite EH and mucosal regeneration. These markers may provide targets for future or sequential therapies.

Persistent desmoglein-1 downregulation and periostin accumulation in histologic remission of eosinophilic esophagitis

A Multicenter Long-Term Cohort Study Of Eosinophilic Esophagitis Variants And Their Progression To Eoe Over Time

Manometric findings in children with eosinophilic esophagitis and persistent post-remission dysphagia

An esophagus cell atlas reveals dynamic rewiring during active eosinophilic esophagitis and remission

"Reducing Eosinophil Counts in Eosinophilic Esophagitis in Children Is Associated with Reduction in Later Stricture Development"

Expression profiling identifies key genes and biological functions associated with eosinophilic esophagitis in human patients

OP04 Endoscopic healing in paediatric IBD perpetuates a persistent signature characterized by pathogenic Th17 cells and tissue-associated molecular and microbial drivers of disease

Characterization of lamina propria remodeling in pediatric eosinophilic esophagitis using second harmonic generation microscopy

Suprabasal cells retain progenitor cell identity programs in eosinophilic esophagitis–driven basal cell hyperplasia

Predictors of persistent symptoms in eosinophilic esophagitis after remission: fibrostenosis, eosinophilia, anxiety, and depression

Mononuclear cell composition and activation in blood and mucosal tissue of eosinophilic esophagitis

Novel transcriptomic panel identifies histologically active oesinophilic oesophagitis

Esophageal microbiome in active eosinophilic esophagitis and changes induced by different therapies

Children with eosinophilic esophagitis non-responsive to combination therapy have distinct esophageal transcriptomic and microbiome profile

Development and dysfunction of structural cells in eosinophilic esophagitis

Eosinophilic esophagitis: novel concepts regarding pathogenesis and clinical manifestations

Long-term durability between parent and child patient-reported outcomes in eosinophilic esophagitis

An update on Eosinophilic Esophagitis

Mucosal Microbiota Associated With Eosinophilic Esophagitis and Eosinophilic Gastritis

Long-Lasting Dissociation of Esophageal Eosinophilia and Symptoms After Dilation in Adults With Eosinophilic Esophagitis

Noninvasive biomarkers identify eosinophilic esophagitis: A prospective longitudinal study in children